INTRODUCTION
Intrauterine adhesions (IUAs) also known as Asherman's syndrome (AS), a consequence of trauma or inflammatory attack to the endometrium, is the main cause of uterine infertility (Asherman, 1948 (Asherman, , 1950 March, 2011b; Schenker and Margalioth, 1982) . For symptomatic IUAs, hysteroscopic adhesiolysis to restore the normal anatomy of the uterine cavity is the only recommended approach (AAGL Elevating Gynecologic Surgery, 2017) . However, the recurrence of IUAs is common and difficult in management, especially severe adhesions (Capella-Allouc et al., 1999; Pabuçcu et al., 1997; Yang et al., 2016) . The endometrium, a unique cyclic tissue regeneration system, is dependent on the cyclical growth and regression of the blood vessels that supply the endometrium (Smith, 2001) . Severe damage of endometrium, in other words, the damage to the subepithelial capillary plexus, leads to the blockage of endometrial regeneration (Gargett and Rogers, 2001; Rafii and Lyden, 2003) . The native cells, including epithelial cells, stromal cells, vascular endothelial cells and immune cells, are replaced by fibroblast cells and myofibroblast cells which produce large amount of extracellular matrix including collagen fibrils, finally lead to the formation of endometrial scarring (Gurtner et al., 2008) . The endometrium in the dense fibrotic areas is thin and atrophic with inactive glands and scant poorly vascularized stroma (Yu et al., 2008; Zhao et al., 2017) , which would prevent embryo from implantation (Healy et al., 2016; Lu et al., 2017) . At present, there are few effective methods to improve the fertility outcomes.
Rapid revascularization of injured, ischemic tissue is essential to restore tissue function. Much effort has been focused on delivering angiogenic factors to accelerate tissue revascularization (Carmeliet, 2000; Khurana and Simons, 2003) . In cardiovascular diseases, the delivery of growth factors improves myocardial and peripheral extremity perfusion and function within ischemic regions. Similarly, the numerous angiogenic promoters that have been identified in human endometrium may regulate angiogenic events and promote endometrial vascularization (Girling and Rogers, 2005; Rogers and Gargett, 1998) . Along with the formation of subepithelial capillary plexus, stem and progenitor cells are recruited and mobilized to the injury site and facilitate restoration of tissue function (Rafii and Lyden, 2003) .
bFGF is a potent in vitro mitogen for capillary endothelial cells, stimulates angiogenesis in vivo (Andrades et al., 2001; Squires et al., 1988) , and plays an important role in wound healing and tissue repair (Fujita et al., 2004; Nakamichi et al., 2016; Risau, 1997; Tabata and Ikada, 1999) . During the menstrual cycle, bFGF is essential for angiogenesis, reepithelialization, blood vessel function and stromal cells proliferation in the endometrium (Virag et al., 2007; Wei et al., 2004) . However, due to the loss of normal endometrium and the reduction of blood vessels, the angiogenic factor bFGF derived from bone marrow and endometrial cells decreases significantly and angiogenesis is impaired (Murayama et al., 2002; Rehman et al., 2003) , which further prevents the endometrial repair and regeneration and forms a vicious circle (Gargett and Rogers, 2001) . Providing additional bFGF may break the cycle, so a controlled delivery system consisting of collagen-targeted bFGF and exogenous collagen was established (Zhao et al., 2007) , and previous animal studies in bladder, neural, abdominal wall regeneration suggested that the bFGF controlled delivery system could promote vascularization and cellularization significantly Shi et al., 2011; Shi et al., 2014) .
In our previous study, we applied the CBD-bFGF delivery system to reconstruct the severe damaged uterine wall and found that CBD-bFGF could promote the functional regeneration of the damaged uterine wall. The pregnancy rate of CBD-bFGF group (86.67%) was close to that of sham operated group (100%), suggesting a nearly full uterine recovery from injury in pregnancy rate (Li et al., 2011) .
In the present study, CBD-bFGF was locally injected around the scarred endometrium after hysteroscopy under the guidance of ultrasound to investigate the safety and effect of CBD-bFGF on human scarred endometrium. Our results demonstrated that CBD-bFGF was safe to the patients and improved endometrial blood flow, increased the endometrial thickness and three patients successfully achieved pregnancy over 20 gestational weeks.
RESULTS

Patient flow and baseline characteristics
Infertile patients were diagnosed by medical history and hysteroscopy with endometrial scarring, the scar area ranged from 30% to 100% (Figure 1 ). The clinical symptoms of those patients included hypomenorrhea/amenorrhea (amenorrhea 1 case, hypomenorrhea 2 cases and the other patients were scant spotting), infertility (ranging from 2 to 8 years, mean infertile duration of (4.5±2.0) years) and 7 of them failed in embryo transfer (Table 1) . They were (34.1±3.1) years old (ranging from 27 to 40 years old). All patients had a history of dilation and curettage (D&C) (average (2.7±1.5) times, 1-6 times) and one patient had the history of resection of septa of uterus. After D&C, 94.4% (17/18) of the patients had hysteroscopic adhesiolysis and 10 of them were graded as severe IUAs for the first hysteroscopy. Fifteen patients underwent repeated hysteroscopic adhesiolysis (2-4 times) due to recurrence of adhesions (Table S1 in Supporting Information). The maximum endometrial thickness achieved after large doses of estrogen stimulation was (4.7±0.9) mm (from 3.2 to 6.3 mm) before treatment, which was not suitable for embryo implantation. Till now no effective ways could help them to conception successfully.
Before the treatment, the thin endometrium was accompanied with poor sub-endometrial blood flow by Doppler sonography (Figure 2A , left panel) and three-dimensional imaging demonstrated narrow endometrial cavity looking like a tube without the shape of uterine horns ( Figure 2B , left panel). Consistently in hysteroscopy, uterine cavity usually lost uterine horns and the endometrium appeared pale, dense fibrotic tissue, lack of glands even in late proliferative phase ( Figure 3 , left panel). They were classified as Va or Vb in ESGE classification of IUAs (Wamsteker and De Block, 1998) . Twenty infertile patients suspected of endometrial scarring were recruited in this study. After detailed history taking, ultrasonic detection of ovulation and hysteroscopy inspection made the diagnosis. The patients who met the inclusion criteria received the first bFGF therapy. Estrogen stimulation was used post-operation to promote endometrial thickening. Four weeks after treatment, ultrasound scan and second look hysteroscopy were arranged. The second time bFGF was injected around scarred endometrium if necessary.
For those whose endometrial thickness reached 7 mm and hysteroscopy indicated normal uterine cavity and normal endometrium, they were advised to try conceiving. One of them refused the second-look hysteroscopy and another one lost to follow up in the third month after the second bFGF injection, so 18 patients were included in the analysis following the steps outlined in the flow chart ( Figure 1 ).
CBD-bFGF was safe for injection into endometrium via cervix
CBD-BFGF (report number: SH201601373) was provided by Institute of Genetics and Developmental Biology, Chinese Academy of Sciences. In order to assess the safety of the CBD-bFGF treatment, we documented the surgical complications, systemic and local adverse events after the surgery including anesthetic accident, uterine perforation, uterine bleeding, and infection. No surgical relative complications were identified during operation and no fever, abdominal pain, allergic reaction and abnormal vaginal discharge took place three days after the operation. The pathological find- ings from the second looking hysteroscopy showed that no inflammatory cell infiltration and no abnormal proliferation were detected from the endometrial biopsies. One year after treatment, no abnormal uterine bleeding and abdominal pain were reported. All patients except pregnant women received ultrasound scan after one year and found uteruses were normal size. Thus, no adverse events occurred throughout the observation period in all patients.
CBD-bFGF injections promoted the endometrial angiogenesis and increase endometrial thickness
All the patients reported longer and heavier menstruation, PBAC score increased significantly (8.00±11.25 vs. 23.61 ±23.43, P<0.01), and the color of menstrual blood usually from the brown to bright red after first CBD-bFGF injection (Table 2, Figure 4 ). The patient with amenorrhea (patient No.3) recovered menstruation 2 months after treatment, although she was back to the status of amenorrhea one year after the first bFGF injection.
After the first injection of CBD-bFGF, one patient's (patient No.10) endometrial thickness reached 8.7 mm and blood flow improved obviously under estrogen stimulation. Both transvaginal ultrasonography and hysteroscopy indicated normal uterine cavity, so she received frozen embryos transfer. Unfortunately, the embryo did not implant and she needs other cycle of IVF. The other 17 patients received the second injection, of whom three patients' (patient No.4, 9, 15) endometrial thickness was increased over 7 mm and three-dimensional imaging by ultrasound scan presented with normal uterine cavity ( Figure 2B , right panel). The hysteroscopy also indicated that they returned to normal uterine shape with the reappearance of uterine horns and the scarred endometrium replaced by normal endometrium ( Figure 3 ). Nine patients did not receive the third injection because there is no obvious improvement so they refused the following treatment (Patient No.1, 3, 6, 18) or the IUA or endometrial scarring reappeared after two natural cycles (Patient No.5, 11, 14, 16) . Three patients received the third injection and two patients received the forth injection. Although the sub endometrial blood flow in five patients was improved (Figure 2A , right panel), their endometrial thickness, although increasing to various extents ((4.72±0.88) mm vs. (5.56±1.49) mm, P<0.01), was not suitable for embryo Figure 4 The PBAC score of the patients before and after bFGF treatment. n=18; **, P<0.01. Figure 5 ). Hysteroscopy showed that after multi-site injection of CBD-bFGF, the hysteroscopy showed a significant reduction of the scar area (54.72% ±22.28% vs. 34.06%±30.23%, P<0.01) ( Figure 6 and Figure  S1 in Supporting Information). The patients who recovered well all had a more than 30% reduction in scar area. There was no obvious difference in terms of endometrial thickness and scarred area between the third and fourth CBD-bFGF injection.
Histological changes before and after the CBD-bFGF treatment
Endometrium samples from the first and subsequent followup hysteroscopic biopsies in 18 patients were studied to determine the histological and molecular changes before and after the treatment. Endometrial samples of all participants were obtained in the late proliferative phase. Compared with the normal control women, the scarred endometrium from patients displayed disordered structure of functional layer and basal layer and featured peeling off the endometrial epithelium, decrease or absence of glands, a reduced density of stromal cells and significant fibrinous deposition in both endometrial and myometrium layers ( Figure S2 in Supporting Information). In four patients recovered well under hysteroscopy, immunohistochemical study showed the upregulation of the von Willebrand factor (vWF), indicating the increase of blood vessel density and improvement of angiogenesis of the endometrium. The upregulation of estrogen receptor-α (ER-α), the decrease of Masson's trichrome stain and α-smooth muscle actin (α-SMA) after the second CBD-bFGF injection indicated the degradation of collagen and the remodeling of scar (Figure 7) . For other patients, they also had the upregulation of vWF after treatment, but there were no obvious improvements in expression of ER-α, α-SMA and Masson's trichrome stain.
bFGF therapy made three patients achieve pregnancy
If no obvious endometrial scarring was found during the hysteroscopic inspection and endometrial thickness reached 7 mm, an embryo transfer (ET) or spontaneous pregnancy was planned for these patients. Among the 18 patients included for analysis, four patients met above criteria for conception (Table 2) . One patient (Patient No.9) became pregnant naturally 3 months after bFGF treatment, she was ongoing pregnant until 22+ weeks but premature rupture of membranes took place and the preterm newborn died after birth. The other three patients accepted embryo transfer, one failed and two conceived successfully, of whom patient No.15 suffered from premature rupture of membranes at 25+ weeks and the preterm newborn died after birth. Patient 4 delivered a healthy boy at 41 +3 weeks and there was no placental complication. One patient (patient No.12) became pregnant due to contraceptive failure but unfortunately, it was an ectopic pregnancy.
DISCUSSION
A subepithelial capillary plexus develops during the menstrual cycle (Gargett and Rogers, 2001) . Proliferative phase vascular growth occurs throughout the functionalis in which, under the influence of oestrogen, the endometrium approximately quadruples in thickness (Rogers and Gargett, 1998) . Blood flow through this plexus reaches a maximum during the early and mid-secretory phases in preparation for the implanting embryo (Gannon et al., 1997) . When the endometrium is damaged by trauma (e.g., D&C) or infection (e.g., endometrial tuberculosis), the subepithelial capillary plexus is impaired and the angiogenic promoters like VEGF, bFGF, which derived from cells within the vasculature, significantly reduce (Gaudry et al., 1997; Taichman et al., Figure 5 The average maximum endometrial thickness in patients before and after bFGF treatment measured by ultrasound. n=18; **, P<0.01.
Figure 6
The scarred endometrial area by hysteroscopy in patients before and after bFGF treatment. n=18; **, P<0.01.
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). Under the circumstances, the recruitment of bone marrow derived stem and progenitor cells is impeded, enzymes that degrade collagen are reduced, a large number of extracellular matrices generate which cannot be degraded timely, and the native functional cells are replaced by fibrous cells (Rafii and Lyden, 2003) . All the changes result in the formation of endometrial fibrosis and patients suffer from hypomenorrhea and infertility (Deans and Abbott, 2010; March, 2011a) . Endometrial fibrosis is the clinical feature of IUA. For the patients with severe IUAs, even if dealt with hysteroscopic adhesiolysis, the endometrial scarring is inevitable. It is a tough problem and there is no effective treatment for these patients. Finding an effective method to promote angiogenesis and endometrial regeneration is our concern. Many growth factors showed great advantages in promoting functional remodeling of old scars and wound healing. Vascular endothelial growth factor (VEGF), one of the most commonly studied angiogenic growth factors, is critical to proliferation of endothelial cells, formation of new vessels, and re-epithelialization of endometrium (Fan et al., 2008; Risau, 1997) . It can promote nerve regeneration and induce reduction of scar size in infarcted hearts (Ma et al., 2014; Zhang et al., 2009) . As a potent mitogenic factor, bFGF has been extensively explored for their potential in wound healing . A systematic review in 2016 demonstrated that in China and Japan, in conditions as diverse as burns, chronic wounds, oral ulcers, vascular ulcers, diabetic ulcers, pressure ulcers and surgical incisions, the use of bFGF showed great efficacy in tissue repair and regeneration and exhibited significant safety (Akita et al., 2008; Beenken and Mohammadi, 2009; Jiang et al., 2013; Nunes et al., 2016; Uchi et al., 2009) . Until now, there are more than 100 registered clinical trials in clinicaltrials.gov about the effect of bFGF on tissue repair. VEGF or bFGF, by either local application or systemic administration, has the limitation of short half-life in vivo (Bush et al., 2001) and low concentrations at the injury site, which lowers its effects inevitably and causes side effects on the surrounding tissues due to the burst effect (Chu and Wang, 2012; Eppler et al., 2002; Silva and Mooney, 2007) . Increasing local concentration and prolonging biological effect of the growth factor are of great significance. Therefore, a system consisting of collagen-targeted bFGF, a collagen-binding domain (CBD), was established (Zhao et al., 2007) , and subsequent studies in bladder, neural, abdominal wall regeneration suggested that the sustained-release system of bFGF could improve the collagen-binding ability and accelerate cellularization of collagen biomaterials, increase neovascularization and promote regeneration (Li et al., 2012; Ma et al., 2014; Shi et al., 2017; Tang et al., 2018; Zhang et al., 2017) . In our previous studies, we applied CBD-VEGF or CBD-bFGF on uterine scar tissue, which promoted remodeling of the scarred uterus and improved pregnancy rate in the full-thickness rat uterus injury model. In addition, the CBD-bFGF provided by the Chinese Academy of Sciences meets the standard for clinical use.
As to the appropriate dose of bFGF injection into endometrium, we referred to the dosage used in previous clinical trials (Hashimoto et al., 2009; Hato et al., 2012; Hirano et al., 2013; Kanazawa et al., 2015; Kawaguchi et al., 2010; Kumagai et al., 2016; Ono et al., 2007) . In patients with critical limb ischemia, fresh tibial shaft fractures, peripheral arterial disease and a sutured wound, the bFGF concentration ranged from 100 μg to 1.2 mg and all significantly improved the symptoms without any serious side effects. Thus the low dosage of 100 μg was chosen to repair the endometrium. The CBD-bFGF released slowly within the adjacent tissues along with the degradation of the collagen over time, which retained less than 20% two weeks later , so repeated injection of CBD-bFGF is needed. Four weeks after the first injection, we gave the second injection.
In order to reduce damage and infection of injecting bFGF into the scarred endometrium by multiple sites, a special syringe needle was invented. The length of the needle is 10 cm and 2 mm from the needle tip, a small ball is designed which is fit for injection into the fundus and avoids uterus perforation. The side opening of the needles, different from normal needle, makes bFGF release into endometrium without blocked by endometrium or dense connective tissue. There are two types of needles, one is straight which is suitable for injection into the fundus, another has a right angle in the needle point suitable for injection into uterine walls under ultrasonic monitoring. The multisite injection guided by ultrasound enables bFGF to distribute uniformly.
In the patients whose scarred endometrial area was close to 100%, even repeated bFGF treatment was in vain. It remains to be seen whether increasing the dosage or adding other angiogenic growth factors will be effective, and further studies are needed. Notably, since those patients may receive the D&C and hysteroscopies several times, there is a high possibility of cervical impairment, leading to cervical incompetence (American College of Obstetricians and Gynecologists, 2014). In our study, patient No.9 experienced 6 times of dilation and curettages, while patient No.15 had cervical conization history and 3 times of dilation and curettages. They both suffered from late abortion due to cervical incompetence. It is suggested to measure the cervical length during early pregnancy. If necessary, cervical cerclage may be considered to decrease the preterm prevalence.
One of our limitations is the small sample size. Further greater sample sizes and randomized controlled clinical studies are required. Besides, analysis from different layers will help determine the indications, for example, the patients with different endometrial thicknesses and different endometrial scarring areas.
In summary, we have demonstrated that CBD-bFGF injection to the endometrium promoted the scar remodeling and improved the endometrial angiogenic and proliferation ability. Therefore, CBD-bFGF may represent a promising growth factor for the treatment of endometrial scarring.
MATERIALS AND METHODS
Ethics approval and consent to participate
The study was approved by the Ethics Committee of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School (No.2016-129-01) . Informed consent was abstained from all the individual participants included in the clinical study. The clinical trial registration number is ChiCTR-OPC-17010786.
Study enrollment and inclusion and exclusion criteria
It was a single-center, prospective cohort study. The study design is summarized in Figure 8 . Criteria for inclusion were 20-40-year-old infertile women, with clear fertility desire, with normal ovarian function or with frozen embryos, willing to follow-up and most importantly those patients were diagnosed with endometrial scarring where drugs and surgical interventions were ineffective. Patients were excluded from the enrollment if they were under any of the following circumstances: with obvious adhesions which can be separated; with abnormal chromosome karyotype; with severe uterine diseases including large intramural myomas, severe adenomyosis, severe congenital uterine malformations, and endometrial tuberculosis; with systemic diseases, such as hypertension and diabetes; with contraindications to pregnancy; with contraindications to hormone replacement therapy (HRT); with medical history of pelvic tumors or receiving pelvic radiotherapy; involved in other clinical study; unable to adhere to the follow-up.
Source of materials
The CBD-bFGF in the form of powder was provided by Institute of Genetics and Developmental Biology, Chinese Academy of Sciences (Beijing, China). It reached clinical application standard by CFDA for only clinical study use.
Hysteroscopic operations and bFGF injection
According to the study design, diagnosis of endometrial scarring was confirmed by an experienced gynecologist at the Drum Tower Hospital, who also performed all hysteroscopy and endometrial biopsies in late proliferative phase before the CBD-bFGF injection. On the third day of menstruation, patients were administered Femoston (2 mg estradiol/10 mg estradiol and dydrogesterone, Abbott Healthcare Products B.V., Netherlands) of 4 mg estradiol per day orally and 2 mg d -1 placed in the vagina for 10-12 days until the day before operation. On the day of the procedure, the gynecologist performed a hysteroscopic evaluation, calculated the scarred area and collected the endometrial biopsies. We assume that the area of the uterine fundus and horns accounted for 20%, the anterior and posterior uterine walls for 60%, and the left and right uterine walls for 20%. Any better way to calculate the scarred area needs further discussion. After that the powder form of CBD-bFGF was diluted with sterile saline and injected into the endometrium by multiple sites with special syringe needle which was designed by our research group (patent number: ZL 2015 2 0425487.8). All the procedures were under the guidance of ultrasound. The areas of scarred endometrium and injected locations were recorded. After bFGF therapy, the patients were treated with Femoston only containing estradiol of 6 mg d -1 for 28 days and measure the endometrial thickness.
Ultrasound measurement
For endometrial thickness, each patient acted as her own control since all of them underwent natural cycles and estrogen stimulating cycles before the bFGF therapy. We measured the endometrial thickness before ovulation under natural cycle or estradiol 6 mg d -1 for 14 days in artificial cycle. We measured at least three cycles both before and after the treatment, using the thickest endometrial thickness for comparison. Endometrial thickness and blood flow was measured by the same experienced sonographer and the same machine. Endometrial thickness means the maximum distance between the myometrial interface of the anterior to the posterior wall in a median longitudinal plane of the uterus. Transvaginal ultrasound examination was performed every time before the hysteroscopy. Transabdominal ultrasound was conducted to detect the pregnancy outcome.
Second-look hysteroscopy
Usually 4 weeks after the first bFGF injection, the secondlook hysteroscopy was performed and endometrial biopsies were collected. If the endometrium thickness was <7 mm, the second round of bFGF therapy was recommended and 6 mg d -1 estradiol was continued for another 20 days until the third-look hysteroscopy. If the endometrium thickness was ≥7 mm after the therapy and hysteroscopy showed the normal uterine cavity and normal endometrium, the patients were allowed to attempt conception. In face of the unsatisfied endometrial repair, we may inject CBD-bFGF for the third time after two natural menstrual cycles and at most we gave four chances for treatment.
Adverse events and safety assessment
Even the guidelines for antibiotic use in gynecologic procedures do not recommend antibiotic use for diagnostic or operative hysteroscopy (ACOG Committee on Practice Bulletins, 2006) . Taking the theoretic risk of secondary infection into consideration, we still used the antibiotic therapy. All the patients were given antibiotics for 3 days after surgery to prevent infection. Other surgical complications such as perforation of the uterus, hemorrhage, pelvic infection and anesthesia accidents were carefully recorded. Besides postoperative vital signs (body temperature, blood pressure, and heart rate), symptoms of allergy were also recorded.
Follow-up and efficacy assessment
All the patients were followed up for at least one year. The primary outcomes were the scarred endometrial area and the endometrial thickness. The secondary outcomes included endometrial blood flow, menstruation history (including duration, volume and frequency), ongoing pregnancy rate (defined as the presence of a living intrauterine fetus at the 12th week of gestation), miscarriage rate and histological changes in the endometrium. It is worth noting that the pregnancy complications remained high risk, including spontaneous abortion, premature delivery, abnormal placentation, intrauterine growth restriction (IUGR), and uterine rupture during pregnancy or delivery.
Hematoxylin-Eosin staining and immunohistochemical analysis
The sections (5 μm) on slides were immersed in xylene (3 min, twice), and rehydrated in a decreasing ethanol series diluted in distilled water (100%, 100%, 95%, 95%, 75%, 0%, 1 min each). The sections were rinsed in water, stained in hematoxylin for 45 s, and rinsed in water. After the staining, the sections were air-dried at room temperature and mounted using Permount TM Mounting Medium. Immunohistochemical staining was used to assess the regeneration and neovascularization of the endometrium. After embedding and sectioning at 2 μm, samples were deparaffinized and rehydrated, and endogenous peroxidase activity was blocked by incubation in H 2 O 2 (Sangon, Shanghai) for 10 min. After heat-mediated antigen retrieval, im- munohistochemical analyses were performed with these primary antibodies (Table S2 in Supporting Information) incubated overnight at 4°C. After washing three times with PBS, the sections were incubated with goat anti rabbit or mouse secondary antibody (Bosterbio, Wuhan) and then stained with DAB reagent (Zhongshan Jinqiao, Beijing) to visualize the antigen signals. Negative controls were performed by omitting the primary antibodies. The sections were counterstained with hematoxylin and viewed under a microscope (DMi8, Leica, Wetzlar, Germany).
Statistical analysis
All descriptive statistics and statistical analysis were performed using GraphPad software (GraphPad Prism 5.0, San Diego, USA) and data are expressed as means±standard error (SE). Statistical comparisons were performed using a pairedsamples t-test, and the rank sum test was performed using the Statistical Program for Social Sciences (SPSS, Inc., Version 21.0, Chicago, IL, USA). Throughout the text, figures and figure legends, values of *P<0.05, **P<0.01 and ***P<0.001 were considered as statistical significant.
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SUPPORTING INFORMATION
Figure S2
H&E staining of endometrial samples from 9 patients before bFGF treatment.
Table S1 Details about the hysteroscopies, adhesiolysis and attempts in embryo transplantation The supporting information is available online at http://life.scichina.com and https://link.springer.com. The supporting materials are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely with the authors.
